BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 9241616)

  • 1. Clinical experience of antibodies to interferon-alpha during treatment of chronic myeloid leukemia.
    Russo D; Candoni A; Grattoni R
    J Interferon Cytokine Res; 1997 Jul; 17 Suppl 1():S47-9. PubMed ID: 9241616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment with lymphoblastoid alpha interferon in patients with chronic myeloid leukemia refractory to recombinant interferon alpha 2].
    Steegmann JL; Granados E; Vázquez L; de la Cámara R; Peñarrubia MJ; Fernández-Contreras E; Quiroga JA; Fernández Rañada JM
    Sangre (Barc); 1998 Oct; 43(5):443-6. PubMed ID: 9868341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Molecular biology follow-up of interferon therapy in patients with chronic myeloid leukemia].
    Iványi JL; Marton E; Kereskai L; Kiss Z; Pajor L
    Orv Hetil; 2000 Nov; 141(47):2527-33. PubMed ID: 11143285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter prospective study of interferon-alpha and conventional chemotherapy versus bone marrow transplantation for newly diagnosed patients with chronic myelogenous leukemia. Kouseisho Leukemia Study Group.
    Ohnishi K; Minami S; Ueda T; Nishimura M; Tsubaki K; Takemoto Y; Takeshita A; Sao H; Kageyama S; Ueda R; Ohno R
    Int J Hematol; 2000 Aug; 72(2):229-36. PubMed ID: 11039674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prior treatment with alpha-interferon does not adversely affect the outcome of allogeneic BMT in chronic phase chronic myeloid leukemia.
    Zuffa E; Bandini G; Bonini A; Santucci MA; Martinelli G; Rosti G; Testoni N; Zaccaria A; Tura S
    Haematologica; 1998 Mar; 83(3):231-6. PubMed ID: 9573677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
    Kantarjian H; O'Brien S; Cortes J; Shan J; Giles F; Garcia-Manero G; Verstovsek S; Faderl S; Rios MB; Talpaz M
    Cancer; 2003 Oct; 98(7):1430-7. PubMed ID: 14508830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
    Kantarjian HM; Talpaz M; O'Brien S; Smith TL; Giles FJ; Faderl S; Thomas DA; Garcia-Manero G; Issa JP; Andreeff M; Kornblau SM; Koller C; Beran M; Keating M; Rios MB; Shan J; Resta D; Capdeville R; Hayes K; Albitar M; Freireich EJ; Cortes JE
    Clin Cancer Res; 2002 Jul; 8(7):2177-87. PubMed ID: 12114418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
    Kantarjian HM; O'Brien S; Cortes J; Giles FJ; Rios MB; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Verstovsek S; Wierda W; Keating M; Talpaz M
    Cancer; 2003 Dec; 98(12):2636-42. PubMed ID: 14669283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective study of alpha-interferon and autologous bone marrow transplantation in chronic myeloid leukemia. The Italian Co-operative Study Group on Chronic Myeloid Leukemia.
    Meloni G; Russo D; Baccarani M; Testoni N; Martinelli G; Fanin R; Zuffa E; Rosti G; Alimena G; Saglio G; Mandelli F; Tura S
    Haematologica; 1999 Aug; 84(8):707-15. PubMed ID: 10457406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-alpha.
    Branford S; Hughes T; Milner A; Koelmeyer R; Schwarer A; Arthur C; Filshie R; Moreton S; Lynch K; Taylor K
    Cancer; 2007 Aug; 110(4):801-8. PubMed ID: 17607681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
    O'Brien S; Giles F; Talpaz M; Cortes J; Rios MB; Shan J; Thomas D; Andreeff M; Kornblau S; Faderl S; Garcia-Manero G; White K; Mallard S; Freireich E; Kantarjian HM
    Cancer; 2003 Sep; 98(5):888-93. PubMed ID: 12942553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon alpha for chronic myeloid leukemia relapsing after allogeneic bone marrow transplantation.
    Steegmann JL; Casado LF; Tomás JF; Sanz-Rodríguez C; Granados E; de la Cámara R; Alegre A; Vázquez L; Ferro MT; Figuera A; Arranz R; Fernández-Rañada JM
    Bone Marrow Transplant; 1999 Mar; 23(5):483-8. PubMed ID: 10100563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon alpha in the treatment of chronic myelogenous leukemia.
    Robak T
    Arch Immunol Ther Exp (Warsz); 1998; 46(6):347-53. PubMed ID: 9883313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Interferon alpha--the drug of choice for patients with chronic myeloid leukemia].
    Klamová H; Vítek A; Michalová K; Brezinová J; Moravcová J; Jelínek J; Cermák J
    Cas Lek Cesk; 1998 Sep; 137(18):552-6. PubMed ID: 9818464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Interferon alpha in the treatment of chronic myeloid leukemia].
    Tóthová E; Fricová M; Stecová N; Svorcová E; Surová M; Kafková A; Guman T; Mudronová B
    Vnitr Lek; 1996 May; 42(5):327-30. PubMed ID: 8768291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-alpha lymphoblastoid in chronic myeloid leukemia patients unresponsive to recombinant IFN alpha 2.
    Steegmann JL; Granados E; Peñarrubia MJ
    Haematologica; 1997; 82(6):731-2. PubMed ID: 9580090
    [No Abstract]   [Full Text] [Related]  

  • 17. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
    Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
    Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of interferon-alpha therapy on lymphocyte subpopulations in patients with chronic myeloid leukemia.
    Sacchi S; Cortes J; Kantarjian H; Talpaz M
    Hematopathol Mol Hematol; 1997-1998; 11(1):41-7. PubMed ID: 9439979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alpha interferon: progress and perspectives in the biotherapy of chronic myelogenous leukemia.
    Habermann TM
    Oncol Nurs Forum; 1989; 16(6 Suppl):8-11. PubMed ID: 2687814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absence of influence of prior treatment with interferon on the outcome of allogeneic bone marrow transplantation for chronic myeloid leukemia.
    Tomás JF; López-Lorenzo JL; Requena MJ; Aguilar R; Steegmann JL; Cámara R; Alegre A; Arranz R; Figuera A; Fernández-Rañada JM
    Bone Marrow Transplant; 1998 Jul; 22(1):47-51. PubMed ID: 9678795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.